NyquistAI
NyquistAI provides an AI-powered platform that aggregates and analyzes over 1 billion life sciences data points, including 770K+ clinical trials and 26 million adverse events, to deliver contextual insights for strategic decision-making. The company also offers Nyquist Scholar, an AI-enabled medical writing screening tool that reduces systematic literature review time by 40-60% and automates PRISMA diagram creation.
- Data & Analytics
- Artificial Intelligence
- Software Only
- Digital Health
- Healthcare Technology
Funding
Raised to date
$6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
$6M · Seed
Announced Mar 2022
Disclosed cumulative: $6M
Founders
Product
Problem
Life sciences professionals face challenges in efficiently retrieving and analyzing the vast amounts of data required for clinical trials, regulatory strategies, and understanding market trends. Traditional data retrieval methods are often time-consuming and may not uncover previously unconsidered insights.
Solution
NyquistAI offers an AI-powered platform designed to aggregate and analyze over 1 billion life sciences data points, delivering actionable insights to enhance decision-making and workflow efficiency. The platform understands context and uncovers insights that are difficult to find using conventional methods. By fine-tuning its AI with a large volume of life sciences data, NyquistAI provides relevant insights for competitive advantage and develops industry-specific applications tailored to organizational workflows. The platform compiles data from global markets, including clinical trials, approved devices and drugs, and adverse event reports, to accelerate innovation and strategic decision-making.
Target Audience
The primary audience includes life science innovators, including professionals in strategy development, innovation, and regulatory affairs, as well as medical device and pharmaceutical companies. The platform is trusted by over 200 global innovators, notified bodies, and former FDA reviewers.
Features
- AI-powered platform fine-tuned with over 1 billion life sciences data points
- Contextual understanding of data to uncover previously unsearchable insights
- Global MedTech and Pharma data platforms compiling data from influential markets worldwide, including the U.S., EU, China, Japan, and Brazil
- Data coverage including 770K+ clinical trials, 3 million+ approved devices, 700K+ approved drugs, and 26 million+ adverse events
- Nyquist Scholar, an AI-enabled medical writing screening tool that reduces systematic literature review time by 40-60% and automates PRISMA flow diagram creation
- Nyquist Scholar's dynamic recommendation engine (Nyquist Score) learns from previously included or excluded papers to reorder unreviewed papers by likelihood of inclusion
- Chat-with-documents functionality in Nyquist Scholar for querying clinical trial endpoints, patient numbers, and paper summaries
- NyquistIQ, a proprietary GenAI tool that automates data analysis, synthesis, and summarization tasks from research papers, reports, and meetings